Neumora Therapeutics reports favorable 162-animal toxicology results
- Neumora Therapeutics (NASDAQ:NMRA) reported favorable results from a repeat 162-animal toxicology study for its NMRA-215 obesity program.
- Following the release of the updated safety data, the company's shares traded down slightly at $1.58.
- The company stated it expects to submit an Investigational New Drug application and initiate Phase 1 trials by late 2026.
Neumora Therapeutics (NASDAQ:NMRA) reported favorable results from a repeat 162-animal toxicology study for its NMRA-215 obesity program.
The company initiated this repeat evaluation after an earlier 142-rat study showed unexpected adverse findings in five animals.
Following a for-cause audit, the company concluded those initial adverse events were unrelated to the actual treatment.
The company stated it expects to submit an Investigational New Drug application in the fourth quarter of 2026.
Following the announcement, Neumora Therapeutics' share price was down at $1.58.
The business stated it expects to initiate a Phase 1 clinical study before the end of 2026.
The highly brain-penetrant oral NLRP3 inhibitor is being developed primarily for obesity and cardiometabolic disease applications.
